Compare Equinor ASA (EQNR) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Cassava Sciences Inc — how do they compare? Equinor ASA trades at $43.61 (market cap $101.62B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Equinor ASA is far larger — about 2579.2× Cassava Sciences Inc's market cap, and Equinor ASA pays a 3.63% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Cassava Sciences Inc for 37 Days on average.
| EQNR | FLNA | |
|---|---|---|
Market Cap | $101.62B | $39.40M |
Volume | 4,991,782 | 759,018 |
Sector | Energy | Health |
52-Week High | $45.75 | $4.64 |
52-Week Low | $22.41 | $0.68 |
Typical Hold Time | 59 Days | 37 Days |
Enterprise Value | $110.31B | -$43.28M |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $41.61, down 3.26% today, with a bearish technical outlook and mixed fundamental performance. The stock shows attractive valuation metrics including P/E of 11.63 and EV/EBITDA of 2.39, but faces declining profit margins from 19.29% in 2022 to 4.76% in 2025. Recent earnings show two beats and one miss, while analyst consensus remains positive with a $87.50 price target representing significant upside potential from current levels.
The investment case balances deep value characteristics against operational headwinds. While valuation appears compelling with strong cash flows and dividend payments, investors face risks from volatile energy markets and margin compression. The 112% upside to consensus target suggests Wall Street sees substantial recovery potential if operational performance improves.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
